Yahoo Finance

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

AUSTIN, Texas, May 22, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will ...

JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Natera, Inc. stands fifth on our list among the most promising stocks. TheFly reported on December 15 ...

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Quantum Leap Healthcare ...
Business Wire

Natera Announces Commercial Payor Coverage for Signatera™

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual ...
CURE

This Test Helped Identify Treatment in Colorectal Cancer Surgery

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival ...
Yahoo Finance

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, ...
Business Wire

Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean ...
Business Insider

New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings

AUSTIN, Texas, May 26, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and ...
Nasdaq

New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer

AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
Nasdaq

Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting

AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular ...
Morningstar

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Signatera detected recurrence prior to imaging and outperformed standard surveillance methods. Personalized ctDNA detection at the end of treatment and on-treatment clearance were strong predictors of ...